Emil Marek Heymans Pallesen

Emil Marek Heymans Pallesen

Auto-generated profile, based on publicly available information

Emil Marek Heymans Pallesen

Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center University of Copenhagen Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Blood
Verified
Journal Article
Open access
PDF file
MGMaria Gluud
Maria Gluud
EPEmil Marek Heymans Pallesen
Emil Marek Heymans Pallesen
TBTerkild Brink Buus
Terkild Brink Buus
Lise Mette Rahbek GjerdrumLise Mette Rahbek Gjerdrum
Lise Mette Rahbek Gjerdrum
LLLise M. Lindahl
Lise M. Lindahl
Niels OdumNiels Odum
Niels Odum
Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms that hamper quality of life and are entry sites for bacterial infection, a major cause of morbidity and mortality in advanced diseases. The mechanism driving the pathological processes that compromise the skin barrier remains unknown. Here, we report increased transepidermal water loss and compromised expression of the skin barrier proteins filaggrin and filaggrin-2 in areas adjacent to TOX-positive T cells in CTCL skin lesions. Malignant T cells secrete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that activate STAT3 signaling and downregulate filaggrin and filaggrin-2 expression in human keratinocytes and reconstructed human epithelium. Consequently, the repression of filaggrins can be counteracted by a cocktail of antibodies targeting these cytokines/receptors, small interfering RNA–mediated knockdown of JAK1/STAT3, and JAK1 inhibitors. Notably, we show that treatment with a clinically approved JAK inhibitor, tofacitinib, increases filaggrin expression in lesional skin from patients with mycosis fungoides. Taken together, these findings indicate that malignant T cells secrete cytokines that induce skin barrier defects via a JAK1/STAT3-dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for patients with CTCL with advanced disease and a compromised skin barrier.

6 March 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
EPEmil M.H. Pallesen
Emil M.H. Pallesen
MGMaria Gluud
Maria Gluud
CVChella Krishna Vadivel
Chella Krishna Vadivel
TBTerkild Brink Buus
Terkild Brink Buus
BRBob de Rooij
Bob de Rooij
Niels OdumNiels Odum
Niels Odum
Staphylococcus aureus is suspected to fuel disease activity in cutaneous T-cell lymphomas. In this study, we investigate the effect of a recombinant, antibacterial protein, endolysin (XZ.700), on S. aureus skin colonization and malignant T-cell activation. We show that endolysin strongly inhibits the proliferation of S. aureus isolated from cutaneous T-cell lymphoma skin and significantly decreases S. aureus bacterial cell counts in a dose-dependent manner. Likewise, ex vivo colonization of both healthy and lesional skin by S. aureus is profoundly inhibited by endolysin. Moreover, endolysin inhibits the patient-derived S. aureus induction of IFNγ and the IFNγ-inducible chemokine CXCL10 in healthy skin. Whereas patient-derived S. aureus stimulates activation and proliferation of malignant T cells in vitro through an indirect mechanism involving nonmalignant T cells, endolysin strongly inhibits the effects of S. aureus on activation (reduced CD25 and signal transducer and activator of transcription 5 phosphorylation) and proliferation (reduced Ki-67) of malignant T cells and cell lines in the presence of nonmalignant T cells. Taken together, we provide evidence that endolysin XZ.700 inhibits skin colonization, chemokine expression, and proliferation of pathogenic S. aureus and blocks their potential tumor-promoting effects on malignant T cells.

1 October 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AWAndreas Willerslev-Olsen
Andreas Willerslev-Olsen
Lise Mette Rahbek GjerdrumLise Mette Rahbek Gjerdrum
Lise Mette Rahbek Gjerdrum
Lise M. LindahlLise M. Lindahl
Lise M. Lindahl
TBTerkild Brink Buus
Terkild Brink Buus
EPEmil M.H. Pallesen
Emil M.H. Pallesen
Niels OdumNiels Odum
Niels Odum

12 September 2025 in Cancer Discovery
Verified
Journal Article
Open access
TBTerkild Brink Buus
Terkild Brink Buus
CVChella Krishna Vadivel
Chella Krishna Vadivel
MGMaria Gluud
Maria Gluud
MNMartin R.J. Namini
Martin R.J. Namini
ZZZiao Zeng
Ziao Zeng
Niels OdumNiels Odum
Niels Odum
Evolution and outgrowth of drug-resistant cancer cells are common causes of treatment failure. Patients with leukemic cutaneous T-cell lymphoma have a poor prognosis because of the development of drug resistance and severe bacterial infections. In this study, we show that most patients with leukemic cutaneous T-cell lymphoma harbor multiple genetically distinct subclones that express an identical clonal antigen receptor but display distinct phenotypes and functional properties. These coexisting malignant subclones exhibit differences in tissue homing, metabolism, and cytokine expression and respond differently to extrinsic factors like Staphylococcus aureus and cancer drugs. Indeed, although S. aureus toxins selectively enhance activation and proliferation of certain subclones, these responsive subclones are also the most intrinsically sensitive to cancer drugs when the stimuli are removed. Consequently, although the divergent evolution of malignant subclones drives aggressiveness, adaptability, and drug resistance by removing extrinsic stimuli and mapping malignant subclones, we can expose inherent vulnerabilities that can be exploited in the treatment of these cancers. Significance: Cancer cells have inherent disparity in hallmark traits, such as aggressiveness and intrinsic drug resistance. We show that segregation of hallmark traits on different coexisting subclones is common and augments adaptability, aggressiveness, and drug resistance of the overall cancer population. Importantly, this segregation exposes vulnerabilities that can be exploited in individualized therapies.

8 March 2026 in Allergy
Verified
Journal Article
Open access
MGMaria Gluud
Maria Gluud
EPEmil M. Pallesen
Emil M. Pallesen
ZZZiao Zeng
Ziao Zeng
MNMartin R. J. Namini
Martin R. J. Namini
CVChella Krishna Vadivel
Chella Krishna Vadivel
Niels OdumNiels Odum
Niels Odum
Background: Skin barrier dysfunction is central to inflammation and susceptibility to infection in atopic dermatitis (AD). Cutaneous T‐cell lymphoma (CTCL) shares clinical similarities with AD and is also associated with a high prevalence of Staphylococcus aureus ( S. aureus ) colonisation. However, the mechanisms driving skin barrier damage in CTCL and the contribution of bacteria remain poorly understood. Methods: We investigate how the interplay between S. aureus (and staphylococcal enterotoxins (SEs)) and primary malignant‐ and non‐malignant T cells affects keratinocyte expression of skin barrier proteins; in vitro, in an EL4 murine lymphoma model of bacteria‐driven tumour progression, and in CTCL patient lesions colonised with SE‐producing S. aureus before and after bacterial eradication by antibiotic treatment. Results: S. aureus and SEs activate malignant and non‐malignant T cells to release barrier‐repressing cytokines, including IL‐4, IL‐13, IL‐22, and OSM, and JAK‐dependent downregulation of filaggrin and loricrin in keratinocytes. In the EL4 model, bacteria‐colonised tumour‐bearing mice show significant filaggrin loss in tumour‐adjacent epidermis, whereas antibiotic‐treated mice maintain near‐normal expression. Clinically, antibiotic eradication of SE‐producing S. aureus partially restores filaggrin and loricrin expression in three of four patients, paralleling reduced inflammatory signalling. Conclusions: SE‐producing S. aureus promotes skin barrier impairment in CTCL through cytokine‐driven, JAK‐dependent repression of structural proteins in keratinocytes. These findings identify microbial–immune crosstalk as a contributor to CTCL skin pathology and provide mechanistic rationale for strategies targeting S. aureus colonisation as adjunctive therapy in CTCL.

6 October 2025
Verified
Other
Open access
PDF file
TBTerkild Brink Buus
Terkild Brink Buus
CVChella Krishna Vadivel
Chella Krishna Vadivel
MGMaria Gluud
Maria Gluud
MNMartin R.J. Namini
Martin R.J. Namini
ZZZiao Zeng
Ziao Zeng
Niels OdumNiels Odum
Niels Odum
S1 shows sample and analysis pipeline overview. S2 shows malignant-associated gene and surface marker expression in PT17. S3 shows single-cell subclone identification by scTCR-seq, transcriptome and copy-number aberration inference. S4 shows subclonal copy-number aberration co-occurence. S5 shows subclone expression profile stability over time. S6 shows subclonal evolution by matching CITE-seq to flow cytometry. S7 shows validation of inferred CNAs by whole-exome and whole-genome sequencing. S8 shows tissue-associated subclone marker expression in PT09. S9 shows subclonal skin homing/retention markers. S10 shows additional subclonally activated pathways. S11 shows subclonal activation by S. aureus enterotoxins. S12 shows additional S. aureus enterotoxin response signature pathways. S13 shows flow validation of S. aureus enterotoxin response group differences. S14 shows subclonal Romidepsin resistance replicates from same patient at two blood draws. S15 shows subclonal response to inflammatory cytokines and Streptococcal SpeC. S16 shows paired TCR V-gene usage of malignant cells. S17 shows validation of flow cytometry gating and malignant purity estimation.